Hypercapnic (Type II) respiratory failure is PaCO2 >50 mmHg, indicating primary ventilation failure from inadequate minute ventilation. Central causes include respiratory depression (sedatives, opioids, CNS disease), neuromuscular weakness (ALS, myasthenia gravis, diaphragmatic paralysis), or decreased drive. Airway obstruction (asthma, COPD, upper airway obstruction) impairs expiration despite effort. Chest wall restriction (obesity, kyphoscoliosis) limits chest movement. The defining feature is that the lungs are mechanically unable to generate adequate ventilation despite adequate oxygenation, so PaO2 may be normal or only mildly reduced.
Understand the distinction between central, neuromuscular, mechanical, and airway causes of hypoventilation. Measure respiratory mechanics (tidal volume, minute ventilation, vital capacity) to identify the problem. Study the acute pH changes from CO2 retention.
Type II respiratory failure does not always have low oxygen; in fact, supplemental oxygen often makes it worse by removing hypoxic respiratory drive. The problem is ventilation, not oxygenation—giving oxygen without addressing the ventilatory cause can precipitate CO2 retention.
From your study of the respiratory system and gas transport, you know that the lungs perform two linked but separable functions: oxygenation (loading O₂ into blood) and ventilation (clearing CO₂ from blood). This distinction is the key to understanding respiratory failure. Type I (hypoxemic) failure occurs when the lungs fail to oxygenate — typically from ventilation-perfusion (V/Q) mismatch, shunt, or diffusion impairment. Type II (hypercapnic) failure is different in kind: it occurs when the lungs fail to ventilate adequately, causing CO₂ to accumulate in the blood regardless of oxygenation status.
The defining threshold is a PaCO₂ above 50 mmHg — the arterial partial pressure of carbon dioxide. Since CO₂ clearance depends almost entirely on minute ventilation (respiratory rate × tidal volume), hypercapnia means minute ventilation has fallen below metabolic demand. The causes organize into four anatomical levels. Central causes involve failure of the brainstem's respiratory drive: opioids, benzodiazepines, and CNS injury suppress the pacemaker neurons that trigger each breath. Neuromuscular causes involve failure of the respiratory pump itself: conditions like ALS, myasthenia gravis, or diaphragmatic paralysis leave patients unable to generate adequate chest expansion even with intact central drive. Chest wall and mechanical causes — severe obesity, kyphoscoliosis, or large pleural effusions — impose a physical load the breathing muscles cannot overcome. Finally, airway obstruction in COPD and severe asthma creates air trapping: lungs inflate but cannot fully deflate, leaving them hyperinflated and mechanically disadvantaged for the next breath, reducing effective alveolar ventilation despite vigorous effort.
The most clinically dangerous misconception about hypercapnic failure concerns supplemental oxygen. In healthy people, both low PaO₂ and high PaCO₂ independently drive breathing, but CO₂ response dominates. In patients with chronic hypercapnia (e.g., severe COPD), the brainstem has adapted to chronically elevated CO₂ and becomes less sensitive to it as a ventilatory stimulus, relying more heavily on hypoxic drive — the low PaO₂ — to maintain respiratory effort. Giving uncontrolled high-flow oxygen in these patients eliminates this hypoxic stimulus and can blunt respiratory drive, precipitating further CO₂ retention. The correct treatment for hypercapnic failure is non-invasive positive pressure ventilation (NIV) — augmenting ventilation mechanically — not oxygen alone.
Arterial blood gas (ABG) analysis reveals a characteristic pattern in hypercapnic failure: elevated PaCO₂ and, unless the kidneys have had time to compensate, a low pH (respiratory acidosis). In chronic hypercapnia, the kidneys retain bicarbonate to buffer the acidosis, so pH may be near-normal even with dramatically elevated CO₂. The bicarbonate level therefore signals acuity: a normal bicarbonate with high CO₂ suggests acute retention; an elevated bicarbonate suggests chronic adaptation with compensation. This ABG interpretation connects gas transport physiology directly to clinical management — recognizing whether hypercapnia is acute or chronic shapes decisions about how aggressively to intervene and how quickly to correct the CO₂.